Experimental PAH Therapy to Be Tested in New Clinical Trial

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

PH_pah experimental

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of orphan diseases and conditions with ineffective current treatments, announced a new license agreement with a leading Japanese pharmaceutical company, Nippon Kayaku. Eiger BioPharmaceuticals aims to develop Nippon Kayaku’s therapeutic drug Bestatin™ (ubenimex) for the treatment of pulmonary arterial hypertension (PAH) and other inflammatory diseases involving the same molecular pathway.


Read more about it: http://bit.ly/1luzOwA